公开(公告)号：EP1074542A4

公开(公告)日：2002-02-06

申请号：EP00905321

申请日：2000-02-24

申请人： EISAI CO LTD

发明人： HANEDA TORU ,  TSURUOKA AKIHIKO ,  KAMATA JUNICHI ,  OKABE TADASHI ,  TAKAHASHI KEIKO ,  NARA KAZUMASA ,  HAMAOKA SHINICHI ,  UEDA NORIHIRO ,  OHWA TAKASHI ,  WAKABAYASHI TOSHIAKI ,  FUNAHASHI YASUHIRO ,  SEMBA TARO ,  HATA NAOKO ,  YAMAMOTO YUJI ,  OZAWA YOICHI ,  TSUKAHARA NAOKO

IPC分类号： A61K31/00 ,  A61K31/38 ,  A61K31/40 ,  A61K31/403 ,  A61K31/404 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/505 ,  A61K31/506 ,  A61P19/00 ,  A61P19/02 ,  A61P27/00 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  A61P43/00 ,  C07D209/04 ,  C07D209/08 ,  C07D209/30 ,  C07D209/42 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12

CPC分类号： C07D401/12 ,  C07D209/04 ,  C07D209/30 ,  C07D209/42 ,  C07D403/12 ,  C07D409/12

摘要： Novel neovascularization inhibitors are constructed to provide antitumor agents which are superior in safety to conventional antitumor agents, are surely efficacious and can be administered over a prolonged period of time. Namely, indole compounds represented by general formula (I) or pharmacologically acceptable salts thereof or hydrates of the same wherein R represents hydrogen, etc.; R and R are the same or different and each represents hydrogen, etc.; R represents hydrogen or lower (C1-4) alkyl; and the ring A represents cyanophenyl, etc., provided that the following cases are excluded; the one where R , R and R are all hydrogen atoms; the one where R and R are both hydrogen atoms; and the one where the ring A is an aminosulfonylphenyl group and R and R are both halogen atoms; and provided that when the ring A is a cyanophenyl, 2-amino-5-pyridyl or 2-halogeno-5-pyridyl group and R is a cyano group or a halogen atom, then at least one of R and R is not hydrogen.

公开(公告)号：EP1243583A4

公开(公告)日：2003-08-20

申请号：EP00985953

申请日：2000-12-27

申请人： EISAI CO LTD

发明人： HANEDA TORU ,  TSURUOKA AKIHIKO ,  KAMATA JUNICHI ,  OKABE TADASHI ,  TAKAHASHI KEIKO ,  NARA KAZUMASA ,  HAMAOKA SHINICHI ,  UEDA NORIHIRO ,  WAKABAYASHI TOSHIAKI ,  FUNAHASHI YASUHIRO ,  SEMBA TARO ,  HATA NAOKO ,  YAMAMOTO YUJI ,  OZAWA YOICHI ,  TSUKAHARA NAOKO ,  OWA TAKASHI

IPC分类号： A61K31/352 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/501 ,  A61P3/10 ,  A61P9/10 ,  A61P19/02 ,  A61P29/00 ,  A61P35/00 ,  A61P43/00 ,  C07D215/38 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D217/26 ,  C07D311/16 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D411/12 ,  C07D417/12 ,  C07D471/04 ,  A61P35/04

CPC分类号： C07D215/38 ,  C07D215/48 ,  C07D217/02 ,  C07D217/22 ,  C07D217/24 ,  C07D217/26 ,  C07D311/16 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D411/12 ,  C07D417/12 ,  C07D471/04

摘要： Heterocyclic compounds having sulfonamide or sulfonylurea groups, specifically heterocyclic compounds of general formula, pharmacologically acceptable salts of the same, or hydrates of both: (|) wherein A is hydrogen, halogeno, optionally halogenated C1-4 alkyl, or the like; B is optionally substituted aryl, monocyclic heteroaryl, or the like; K is a single bond or the like; T, W, X and Y are each independently =C(D) - (wherein D is hydrogen, halogeno, or the like) or nitrogen; U and V are each independently =C(D) -, nitrogen, oxygen, or the like; Z is a single bond or -CO-NH-; and R1 is hydrogen or the like.

摘要翻译： 本发明提供了含磺酰胺或磺酰脲的杂环化合物。 具体地说，提供由式（I）表示的杂环化合物，其药学上可接受的盐或它们的水合物。 式中，A为氢原子，卤素原子，可被卤素原子取代的C1-C4烷基或烷氧基或氰基; B是任选取代的芳基或单环杂芳基，或：（其中，环Q是可具有氮原子的芳环;环M是与环Q共享双键的环，其中 环可以具有杂原子;并且环Q和M可以共享氮原子）; K是单键; T，W，X和Y彼此相同或不同，并且各自为= C（D） - （其中，D为氢或卤素原子）或氮原子; U和V彼此相同或不同，并且各自为= C（D） - ，氮原子，-CH 2 - ，氧原子或-CO-; Z是单键或-CO-NH-; R1为氢原子等

公开(公告)号：EP0679641A4

公开(公告)日：1996-03-20

申请号：EP94921819

申请日：1994-07-26

申请人： EISAI CO LTD

发明人： YOSHINO HIROSHI ,  UEDA NORIHIRO ,  NIIJIMA JUN ,  HANEDA TORU ,  KOTAKE YOSHIHIKO ,  YOSHIMATSU KENTARO ,  WATANABE TATSUO ,  NAGASU TAKESHI ,  TSUKAHARA NAOKO ,  KOYANAGI NOZOMU ,  KITO KYOSUKE

IPC分类号： C07C211/55 ,  C07C229/58 ,  C07C311/29 ,  C07D209/88 ,  C07D219/04 ,  C07D219/06 ,  C07D219/08 ,  C07D221/12 ,  C07D223/22 ,  C07D243/38 ,  C07D265/38 ,  C07D267/18 ,  C07D267/20 ,  C07D279/20 ,  C07D281/14 ,  C07D413/12 ,  C07D498/04 ,  C07D513/04 ,  C07F7/18 ,  C07D241/46 ,  C07D253/06 ,  C07D279/14

CPC分类号： C07D219/04 ,  C07C211/55 ,  C07C229/58 ,  C07C311/29 ,  C07D209/88 ,  C07D219/06 ,  C07D219/08 ,  C07D221/12 ,  C07D223/22 ,  C07D243/38 ,  C07D265/38 ,  C07D267/18 ,  C07D267/20 ,  C07D279/20 ,  C07D281/14 ,  C07D413/12 ,  C07D513/04 ,  C07F7/1856

摘要： Novel antitumor sulfonamide and sulfonic ester derivatives each having a tricyclic hetero ring, represented by general formula (I), and a process for producing the same, wherein G represents a 5- or 6-membered aromatic ring; L represents O or NR1, wherein R1 represents hydrogen or lower alkyl; and M represents a tricyclic structure selected from the members (a), (b), (c), (d), (e), (f), wherein rings A and B represent each a 5- or 6-membered unsaturated ring; X represents NR2 (wherein R2 represents hydrogen or lower alkyl) or NHCO; Y represents O, S(O)¿n?, CR?3R4¿, CO, NR?5, CHR6CHR7, CR8=CR9, NR10¿CO, N=CR?11, OCHR12¿, S(O)¿n?CHR?13 or NR14CHR15¿; and Z represents N or CR16, wherein n represents 0, 1 or 2; R?3-R13, R15 and R16¿ represent each hydrogen or lower alkyl; and R14 represents hydrogen, lower alkyl or lower acyl.